ALDERAAN BIOTECHNOLOGY

Modulating Immune
Cells to Treat Cancer

ALDERAAN BIOTECHNOLOGY

Mission

The mission of Alderaan Biotechnology is to develop novel therapies to treat cancer by targeting cells from the immune system.

Alderaan Biotechnology programs are related to the elimination of Regulatory T cells and to the hyper activation of Natural Killer cells in the tumor microenvironment.

ALDERAAN BIOTECHNOLOGY

Science

The company programs are based on the research of its founding scientists on the use of monoclonal antibodies targeting immune cells to treat cancers. The objective of Alderaan Biotechnology is to develop new antibodies targeting NK cells through CD160-TM and Treg cells through CD25, with oncology as the sole indication focus.

CD160TM

NK cell boost using CD160-TM specific monoclonal antibodies

CD25

Treg depletion using CD25-specific, IL2 and effector T-cell sparing antibodies

ALDERAAN BIOTECHNOLOGY

News & Events

The 2021 Biotech Trophy 329 293 gloria

The 2021 Biotech Trophy

Alderaan won the 2021 Biotech Trophy of the “Trophées de la Healthtech” hosted by France…

read more

Find out all the news of
Alderaan Biotechnology

Check the online presentation of Alderaan Biotechnology #BioEurope 2021 @AlderaanBiotec1 @AdventFrance @InsermTransfert @medicxi #biotech #cancerresearch

Load More...